All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub was pleased to speak to Meral Beksac, Ankara University, Ankara, TR. We asked, What might be the advantages and disadvantages of treating with daratumumab upfront?
What might be the advantages and disadvantages of treating with daratumumab upfront?
In this video, Beksac discusses the recent relevant data from ASH 2021 that compared the use of frontline daratumumab with other regimens. Beksac comments on the differences in survival rates when daratumumab is given as a frontline treatment, compared with VRd and Rd regimens. Finally, Beksac talks about the Cassiopeia trial.
IMW 2019 | MRD in myeloma
This article provides a summary of talks by Dr Paiva and Dr Gay from IMW 2019, as well as the debate between Prof. San Miguel and Prof. Jagannath
Phase II GRIFFIN study topline results released
The study has met its primary endpoint with a higher percentage of patients achieving a stringent complete response (sCR) with dara-VRd compared to VRd alone
Subscribe to get the best content related to multiple myeloma delivered to your inbox